Clinical Trial

Transformative Research in Diabetic Nephropathy 2.0

Study acronym: TRIDENT 2
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care. The main questions this study aims to answer are: * Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them? * Are these kidney tissue patterns linked with how kidney health changes over time? Researchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines. Participants will: Let researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time
Trial Details
NCT Number NCT07444203
Lead Sponsor University of Pennsylvania
Collaborators: GlaxoSmithKline, Boehringer Ingelheim, Regeneron Pharmaceuticals, Novo Nordisk A/S, AstraZeneca, Genentech, Inc.
Conditions Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Enrollment 200 participants
Start Date 2025-11-12
Primary Completion 2027-05-30 (estimated)
Study Completion 2028-11-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-02